@article{APS11086,
author = {Xiu-chun Li and Xia-yan Zhu and Yang-yue Wang and Shuo-lan Tong and Zhi-li Chen and Zi-yi Lu and Jian-hao Zhang and Lan-lan Song and Xing-hong Wang and Chi Zhang and Yi-han Sun and Chu-yue Zhong and Li-huang Su and Liang-xing Wang and Xiao-ying Huang},
title = {Canagliflozin alleviates pulmonary hypertension by activating PPARγ and inhibiting its S225 phosphorylation},
journal = {Acta Pharmacologica Sinica},
volume = {45},
number = {9},
year = {2024},
keywords = {},
abstract = {Pulmonary hypertension (PH) is a progressive fatal disease with no cure. Canagliflozin (CANA), a novel medication for diabetes, has been found to have remarkable cardiovascular benefits. However, few studies have addressed the effect and pharmacological mechanism of CANA in the treatment of PH. Therefore, our study aimed to investigate the effect and pharmacological mechanism of CANA in treating PH. First, CANA suppressed increased pulmonary artery pressure, right ventricular hypertrophy, and vascular remodeling in both mouse and rat PH models. Network pharmacology, transcriptomics, and biological results suggested that CANA could ameliorate PH by suppressing excessive oxidative stress and pulmonary artery smooth muscle cell proliferation partially through the activation of PPARγ. Further studies demonstrated that CANA inhibited phosphorylation of PPARγ at Ser225 (a novel serine phosphorylation site in PPARγ), thereby promoting the nuclear translocation of PPARγ and increasing its ability to resist oxidative stress and proliferation. Taken together, our study not only highlighted the potential pharmacological effect of CANA on PH but also revealed that CANA-induced inhibition of PPARγ Ser225 phosphorylation increases its capacity to counteract oxidative stress and inhibits proliferation. These findings may stimulate further research and encourage future clinical trials exploring the therapeutic potential of CANA in PH treatment.},
issn = {1745-7254}, url = {http://www.chinaphar.com/article/view/11086}
}